
Faculty, Staff and Student Publications
Publication Date
12-13-2022
Journal
Cell Reports
Abstract
The cancer metastasis process involves dysregulated oncogenic kinase signaling, but how this orchestrates metabolic networks and signal cascades to promote metastasis is largely unclear. Here we report that inhibition of glutamate dehydrogenase 1 (GDH1) and ribosomal S6 kinase 2 (RSK2) synergistically attenuates cell invasion, anoikis resistance, and immune escape in lung cancer and more evidently in tumors harboring epidermal growth factor receptor (EGFR)-activating or EGFR inhibitor-resistant mutations. Mechanistically, GDH1 is activated by EGFR through phosphorylation at tyrosine 135 and, together with RSK2, enhances the cAMP response element-binding protein (CREB) activity via CaMKIV signaling, thereby promoting metastasis. Co-targeting RSK2 and GDH1 leads to enhanced intratumoral CD8 T cell infiltration. Moreover, GDH1, RSK2, and CREB phosphorylation positively correlate with EGFR mutation and activation in lung cancer patient tumors. Our findings reveal a crosstalk between kinase, metabolic, and transcription machinery in metastasis and offer an alternative combinatorial therapeutic strategy to target metastatic cancers with activated EGFRs that are often EGFR therapy resistant.
Keywords
Humans, Cyclic AMP Response Element-Binding Protein, Ribosomal Protein S6 Kinases, 90-kDa, ErbB Receptors, Lung Neoplasms, Phosphorylation, Cell Line, Tumor, CP: Cancer, CREB, EGFR, EGFR mutations, GDH1, RSK2, cAMP response element-binding protein, epidermal growth factor receptor 1, glutamate dehydrogenase 1, metastasis, non-small cell lung carcinoma, oncogenic kinase signaling, ribosomal S6 kinase 2, tumor, tyrosine phosphorylation
DOI
10.1016/j.celrep.2022.111827
PMID
36516759
PMCID
PMC9813823
PubMedCentral® Posted Date
1-5-2023
PubMedCentral® Full Text Version
Author MSS
Graphical Abstract
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons